IntegraGen reports 6.4 M€ in revenues for the first half of 2022 representing 34% growth compared to H1 2021. Cash position of 4.5 M€.

Chiffre affaires en croissance pour IntegraGen - Premier semestre 2021
Continued sustained growth associated with the company’s sequencing platform in Évry and long-term contracts Strong revenue growth linked with microbiology sequencing

Evry, France, Wednesday July 13th 2022, 7.30am – IntegraGen (FR0010908723 – ALINT ), an OncoDNA Group company specializing in the decryption of the human genome which performs (…)  » 

IntegraGen Reports Results for 1st Half of 2020

IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.

Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and  confirms (…)  » 

COMBINED GENERAL ASSEMBLY

integragen

IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France

Click here for more (…)  » 

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…)  »